Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036435 · ClinicalTrials.gov registry record · Phase 3
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
A Phase 3 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 1,466
- Enrollment target
- 20
- Study locations
NCT04036435: Active Phase 3 study of Psoriasis, sponsored by Bristol-Myers Squibb.
NCT04036435 is a Phase 3 study of Psoriasis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,466 participants, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (207% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04036435, a Phase 3 study of Psoriasis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study. In addition, the study includes a vaccine cohort to evaluate whether deucravacitinib impacts the humoral immune response to 2 non-live vaccines, the Pneumovax 23 vaccine (pneumococcus), a T-cell independent vaccine, and the Boostrix vaccine (tetanus toxoid), a T-cell dependent vaccine. Additionally, this vaccine cohort assesses the safety of administering these vaccines to subjects with psoriasis receiving deucravacitinib compared to those receiving a placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-986165
Study Locations (20)
California
- Local Institution - 0046 - Fountain Valley
- Local Institution - 0206 - Fresno
- Local Institution - 0017 - Irvine
- Interspond - Long Beach Clinical Trials - Long Beach
- Dermatology Research Associates - Los Angeles - Los Angeles
- Local Institution - 0236 - Los Angeles
- University of California San Diego Health Systems - San Diego
- Therapeutics Clinical Research - San Diego
- University Dermatology Group - San Diego
- Local Institution - 0094 - San Luis Obispo
- Clinical Science Institute - Santa Monica
- NorthBay Clinical Research - Santa Rosa
Arizona
- Alliance Dermatology and Mohs Center - Phoenix - Phoenix
- Arizona Research Center - Phoenix
- Synexus - Orange Grove Family Practice - Tucson
Arkansas
- Johnson Dermatology - Fort Smith
- Burke Pharmaceutical Research - Hot Springs
- Northwest Arkansas Clinical Trials Center, PLLC - Rogers
Alabama
- Total Skin and Beauty Dermatology Center - Birmingham
- Local Institution - 0278 - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,466 participants |
| Start Date | 2019-08-12 |
| Est. Completion | 2026-07-26 |
| Phase | Phase 3 |
What the registry record for NCT04036435 still lists
NCT04036435 is an interventional study that assigns participants to a tested intervention. Its 1,466 participants enrollment target places it among the larger protocols in the corpus, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (207% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04036435 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04036435 about?
NCT04036435 is a clinical study titled "Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis". The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have been previously enrolled in an applicable Phase 3 psoriasis study. In addition, the study includes a vaccine cohort to evaluate whether deucravacitinib im...
What is the current status of trial NCT04036435?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,466 participants. The study started on 2019-08-12. Estimated completion is 2026-07-26.
What conditions does trial NCT04036435 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT04036435?
The interventions under investigation include: Placebo (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT04036435?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04036435 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04036435's enrollment target sits among peer trials
1,466 7th of 125 higher than 119 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
-
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI